CJC-1295 + Ipamorelin and Tesamorelin Together: What Is Known
CJC-1295 + Ipamorelin and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 6 results, 2 Oct 2026).
Side by side
Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.
| Field | CJC-1295 + Ipamorelin | Tesamorelin |
|---|---|---|
| Class | GHRH + GHRP blend | GHRH analog |
| Also called | CJC/Ipa | tesa, Egrifta |
| Category | Growth hormone | Growth hormone |
| FDA status | Not FDA approved · research blend | FDA approved (Egrifta) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times. | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. |
| Anti-doping detection |
|
|
| Half-life | Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) |
| Evidence strength | Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030 | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 |
| Human studies we summarised | 6 human (3 randomized or controlled) of 19 summarised, across ingredients | 12 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 10 mg | 2 mg, 5 mg, 10 mg, 20 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
CJC-1295 + Ipamorelin vs Tesamorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
A research blend against an approved drug
In rats, ipamorelin released growth hormone with potency and efficacy comparable to GHRP-6. Antagonist profiling indicated it acts through a GHRP-like receptor.[16]
Tesamorelin binds the growth-hormone-releasing-factor receptor with similar potency to the endogenous hormone, per its label's in vitro data.[9]
A review of GH-axis peptides sorts them into evidence tiers from regulatory-grade randomised trials to a complete absence of human studies, and highlights uncertainty around the putative performance and recomposition benefits.[17]
Has the blend or any of its parts met tesamorelin in a trial?
A PubMed search on 2 Oct 2026 for CJC-1295 plus ipamorelin together with tesamorelin matched 6 records; none is recorded as a trial of the combination.
Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 6; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
A randomised trial of ipamorelin for postoperative ileus after bowel resection found no significant difference from placebo in its key and secondary efficacy analyses.[5]
CJC-1295's human trials in healthy adults tracked GH, IGF-I and pharmacokinetics rather than body composition.[6]
Regulatory and sport status
FDA's note on ipamorelin cites a study where serious adverse events including death occurred when it was given intravenously for gut motility.[18]
For CJC-1295, FDA's note names a raised heart rate and a systemic vasodilatory reaction among serious adverse events.[18]
Egrifta WR's label lists active malignancy as a contraindication.[9]
WADA lists the GHRH class that names CJC-1295 and tesamorelin, and separately names ipamorelin among secretagogues.[2]
Common questions
CJC-1295 ipamorelin vs tesamorelin: which is better?
The cached sources include a randomised outcome trial and an FDA label for tesamorelin. None tests the CJC-1295 and ipamorelin blend itself.[15]
Can you stack tesamorelin with CJC-1295 and ipamorelin?
No study in the cached results tested the three together. Tesamorelin's label says the effects of prolonged IGF-1 elevation are unknown.[9]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 4Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 5Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 6Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 7An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 8Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 9EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 11Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 13PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
- 17The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 18Official web pageOfficial web page · web page
Found an error? Report a correction.